Related Experiment Video
Updated: Mar 16, 2026

Tear-Derived Exosomal miR-15a as New Diagnostic Tool for Diabetic Retinopathy
Published on: December 30, 2025
Increased expression of microRNA-155 in peripheral blood mononuclear cells from psoriasis patients is related to
S García-Rodríguez1, S Arias-Santiago2, G Blasco-Morente2
1Department of Cellular Biology and Immunology, Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Parque Tecnológico de la Salud de Granada (PTS Granada), Av. Conocimiento, 17, Granada-18016, Spain.
Background:
MicroRNAs (miRNAs) gene expression regulators are altered in psoriasis suggesting their role in the pathogenesis.
Objective:
To study expression changes of inflammation and toll-like receptor (TLR)-related miRNAs, miRNA-155, let-7i, miRNA-21, miRNA-146a and miRNA-223 in peripheral mononuclear cells (PBMCs) and miRNA-21, miRNA-146a and miRNA-223 in plasma, from chronic plaque-type psoriasis patients who were treatment-naive or had undergone a washout period (n = 11). MiRNAs were evaluated at baseline and after 11 (9-12) months [median (25th-75th percentile range)] of methotrexate (MTX) or topical (betamethasone plus calcipotriene) treatment.
Methods:
MiRNA expression was analysed with quantitative real-time reverse transcription-polymerase chain reaction. Matched controls were studied.
Results:
Psoriasis patients presented, at baseline, increased expression of miRNA-155, let-7i, miRNA-146a, miRNA-21 and miRNA-223 in PBMCs, plus miRNA-21, miRNA-146a and miRNA-223 in plasma. Receiver-operator characteristic (ROC) curve analysis and area under the curve (AUC) showed that expression of these miRNAs have the potential to distinguish between psoriasis and controls. At baseline, miRNA-155 expression in PBMCs correlated with Psoriasis Area Severity Index (PASI) [12 (8-14)] (Spearman r: 0.7140, P < 0.05) suggesting a role in psoriasis. After MTX or topical treatment, reduction in PASI was observed [87.5% (75-100)]; miRNA-155 expression in PBMCs decreased; plasma miRNA-21, miRNA-146a and miRNA-223 were down-regulated. ROC analysis showed that miRNA-155 expression in PBMCs from psoriasis patients have the potential to distinguish between patients' samples at baseline and after treatment (AUC: 0.942, sensitivity: 0.91; specificity: 0.91 values; maximum likelihood ratio =10). After treatment, miRNA-146a expression in PBMCs increased; miRNA-155/miRNA-146a ratio decreased, suggestive of a regulatory feedback; let-7i expression decreased; miRNA-21 and miRNA-223 remained elevated.
Conclusion:
In this exploratory study, psoriasis patients presented increased expression of miRNA-155 in PBMCs that correlated with PASI and decreased with disease remission. MiRNA-21, miRNA-146a and miRNA-223 in PBMCs and plasma were increased at baseline and differentially modulated, underscoring different roles of TLR-related miRNAs in psoriasis.
Insights
Psoriasis patients show elevated levels of specific microRNAs (miRNAs) in blood and cells, which correlate with disease severity. Treatment reduces these miRNA levels, indicating their role in psoriasis pathogenesis and potential as biomarkers.
Area of Science:
- Dermatology
- Molecular Biology
- Immunology
Background:
- MicroRNAs (miRNAs) are key gene regulators implicated in various diseases.
- Altered miRNA expression is observed in psoriasis, suggesting their involvement in the condition's development.
Purpose of the Study:
- To investigate the expression of inflammation and toll-like receptor (TLR)-related miRNAs in psoriasis patients.
- To analyze changes in miRNA levels in peripheral blood mononuclear cells (PBMCs) and plasma before and after treatment.
Main Methods:
- Quantitative real-time reverse transcription-polymerase chain reaction (qRT-PCR) was used to measure miRNA expression.
- Expression levels were analyzed in treatment-naive psoriasis patients and matched controls.
Main Results:
- Psoriasis patients exhibited increased baseline expression of specific miRNAs (miRNA-155, let-7i, miRNA-21, miRNA-146a, miRNA-223) in PBMCs and plasma.
- miRNA-155 expression in PBMCs correlated with Psoriasis Area Severity Index (PASI).
- Treatment led to reduced PASI scores and modulated miRNA expression, with miRNA-155 decreasing and plasma miRNAs (miRNA-21, miRNA-146a, miRNA-223) down-regulating.
Conclusions:
- Elevated miRNA-155 in PBMCs is linked to psoriasis severity and decreases with treatment remission.
- Specific miRNAs (miRNA-21, miRNA-146a, miRNA-223) in PBMCs and plasma are upregulated at baseline and modulated by treatment.
- These findings highlight the distinct roles of TLR-related miRNAs in psoriasis pathogenesis.
More Related Videos
08:12Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
Published on: March 14, 2019
11:06Genome-wide Analysis of HDAC Inhibitor-mediated Modulation of microRNAs and mRNAs in B Cells Induced to Undergo Class-switch DNA Recombination and Plasma Cell Differentiation
Published on: September 20, 2017
Related Concept Videos
MicroRNAs
MicroRNAs
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...